Armistice Capital’s Outlook Therapeutics OTLK Stock Holding History

Armistice Capital’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,168,000	Closed	-$858K	–	395
2026 Q1	$858K	Buy	+4,168,000	New	+$1.8M	0.02%	167
2024 Q2	–	Sell	-714,285	Closed	-$8.53M	–	350
2024 Q1	$8.53M	Buy	+714,285	New	+$5.78M	0.11%	104
2020 Q2	–	Sell	-70,619	Closed	-$849K	–	90
2020 Q1	$849K	Buy	+70,619	New	+$1.17M	0.05%	74

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

Armistice Capital's OTLK Position: Q2 2026 in Review

Armistice Capital sold out of Outlook Therapeutics (OTLK) in Q2 2026, closing a stake of 4,168,000 shares — an estimated $858K sold.

Armistice Capital first reported a position in OTLK in Q1 2020 and held it in 3 quarters. The position peaked at $8.53M in Q1 2024. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Armistice Capital reported no remaining Outlook Therapeutics position as of Q2 2026 after selling out during the quarter.
Armistice Capital sold 4,168,000 Outlook Therapeutics shares in Q2 2026, an estimated $858K.
Armistice Capital first reported a position in Outlook Therapeutics in Q1 2020 and held it in 3 quarters.
Armistice Capital's Outlook Therapeutics position peaked at $8.53M in Q1 2024.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.